Jennifer Judy,1 Michael T Durheim,2,3,4 Shaun Bender,5 Megan L Neely,2,3 Dorothy Baumer,1 Scott B Robinson,1 Craig S Conoscenti,5 Thomas B Leonard,5 Howard M Lazarus,5 Scott M Palmer2,3

1Premier Inc., Charlotte, North Carolina, USA; 2Duke Clinical Research Institute, Durham, North Carolina, USA; 3Duke University Medical Center, Durham, North Carolina, USA; 4Department of Respiratory Medicine, Oslo University Hospital - Rikshospitalet, Oslo, Norway; 5Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.

Introduction

  • Hospitalizations are common in patients with idiopathic pulmonary fibrosis (IPF) and are associated with high mortality.1–3
  • The Premier Healthcare Database (PHD) is a broadly representative dataset that includes >20% of hospital admissions in the US.
  • Based on the PHD, among 6665 patients with IPF who were hospitalized between October 2011 and October 2014, in-hospital mortality was approximately 14% and average length of hospital stay was approximately 5 days.3
  • Two antifibrotic drugs, nintedanib and pirfenidone, were approved for the treatment of IPF in the US in October 2014.
Header - Navigation Icon
Header - Navigation Icon
 Aims

This study was funded by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI) as a collaboration with the Duke Clinical Research Institute and Premier, Inc.